Evaluation of Serum Ages Levels in Patients With Endometriosis
- Conditions
- Endometriosis
- Interventions
- Other: Advanced Glycation End Products (AGEs)
- Registration Number
- NCT04886024
- Brief Summary
Serum AGES (Advanced Glycation End Products) levels of endometriosis patients are compared with a group of healthy volunteers of the same age.
- Detailed Description
Serum AGES (Advanced Glycation End Products) levels are compared with 45 endometriosis patients and 45 healthy volunteers of the same age. The energy metabolism of the endometriosis group and its possible relationship with the endometriosis stage will be compared since AGES (Advanced Glycation End Products) gives information about the energy metabolism of the people.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 90
- diagnosed with endometriosis (Surgery or ultrasound)
- Women without endometriosis
- Women without endometriosis women who are only suspected endometriosis
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description control Advanced Glycation End Products (AGEs) It consists of healthy women between the ages of 18-45 women with endometriosis Advanced Glycation End Products (AGEs) It consists of women between the ages of 18-45 who have been diagnosed with endometriosis by surgery or ultrasonography.
- Primary Outcome Measures
Name Time Method Serum Advanced Glycation End Products (AGEs) levels in women with endometriosis 8 months Serum Serum Advanced Glycation End Products (AGEs) levels involved in inflammation and energy metabolism are compared between endometriosis and healthy control group
- Secondary Outcome Measures
Name Time Method Comparison of the relationship between serum Serum Advanced Glycation End Products (AGEs) level and endometriosis stage 8 months By comparing the relation of serum Advanced Glycation End Products (AGEs) level with the stage of endometriosis, its relation with serum level in patients with advanced and early stage endometriosis will be examined. The possible effect of Advanced Glycation End Products (AGEs) on disease pathogenesis will be examined.
Trial Locations
- Locations (1)
Pinar Yalcin Bahat
🇹🇷Istanbul, İ̇stanbul, Turkey